4/3
08:07 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $65.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $65.00 price target on the stock.
4/2
04:30 pm
jspr
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Medium
Report
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
3/28
08:07 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $70.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $70.00 price target on the stock.
3/22
10:51 am
jspr
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
Low
Report
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
3/21
04:44 pm
jspr
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]
Low
Report
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]
3/21
04:30 pm
jspr
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Low
Report
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
3/20
09:07 am
jspr
Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders are retail investors with 42% ownership, institutions own 26% [Yahoo! Finance]
Medium
Report
Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders are retail investors with 42% ownership, institutions own 26% [Yahoo! Finance]
3/19
08:13 am
jspr
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria [Yahoo! Finance]
Medium
Report
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria [Yahoo! Finance]
3/19
08:00 am
jspr
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
Medium
Report
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
3/18
08:19 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at TD Cowen. They set an "outperform" rating on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at TD Cowen. They set an "outperform" rating on the stock.
3/15
08:23 am
jspr
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia [Yahoo! Finance]
Medium
Report
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia [Yahoo! Finance]
3/15
08:00 am
jspr
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
Low
Report
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
3/14
01:52 pm
jspr
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know [Yahoo! Finance]
Medium
Report
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know [Yahoo! Finance]
3/7
08:25 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $80.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $80.00 price target on the stock.
3/6
10:34 am
jspr
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going [Yahoo! Finance]
Medium
Report
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going [Yahoo! Finance]
3/4
07:43 am
jspr
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments [Yahoo! Finance]
Low
Report
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments [Yahoo! Finance]
3/4
07:30 am
jspr
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
Low
Report
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
2/26
04:30 pm
jspr
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
Low
Report
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
2/23
08:00 am
jspr
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Low
Report
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
2/19
11:08 am
jspr
Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength [Yahoo! Finance]
Low
Report
Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength [Yahoo! Finance]
2/7
08:00 am
jspr
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
High
Report
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
2/6
09:12 am
jspr
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock [Yahoo! Finance]
Medium
Report
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock [Yahoo! Finance]
2/6
08:59 am
jspr
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
High
Report
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
2/5
08:12 am
jspr
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting [Yahoo! Finance]
Medium
Report
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting [Yahoo! Finance]
2/5
08:00 am
jspr
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Medium
Report
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting